|
Yale Cancer Center NCTN
|
5U10CA180826-03
|
$551,500
|
$27,575
|
HOCHSTER, HOWARD
|
YALE UNIVERSITY
|
|
Winship Cancer Institute, National Clinical Trials Network Lead Academic Particip
|
5U10CA180864-03
|
$542,807
|
$20,355
|
RAMALINGAM, SURESH
|
EMORY UNIVERSITY
|
|
Vanderbilt Network Lead Academic Participating Site for the NCTN
|
5U10CA180847-03
|
$9,808
|
$490
|
BERLIN, JORDAN
|
VANDERBILT UNIVERSITY
|
|
Vanderbilt Network Lead Academic Participating Site for the NCTN
|
6U10CA180847-04
|
$410,211
|
$20,511
|
BERLIN, JORDAN
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
|
5U10CA180870-03
|
$645,976
|
$16,149
|
GERBER, DAVID
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
|
3U10CA180870-02S1
|
$50,000
|
$1,250
|
SCHILLER, JOAN
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)
|
5U10CA180858-03
|
$1,192,600
|
$29,815
|
ENG, CATHY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Urologic Oncology Research Training Grant
|
5T32CA082088-17
|
$275,994
|
$41,399
|
CARVER, BRETT
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Urologic Oncology Branch Consult Core
|
ZID BC 011092
|
$1,804,021
|
$360,804
|
Linehan, W. Marston
|
CCR (NCI)
|
|
Urinary Diversion Among Bladder Cancer Survivors: Cost, Complications, and QOL
|
4R01CA164128-05
|
$586,158
|
$586,158
|
MCMULLEN, CARMIT
|
KAISER FOUNDATION RESEARCH INSTITUTE
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-28S1
|
$198,450
|
$3,969
|
LAWRENCE, THEODORE
|
UNIVERSITY OF MICHIGAN
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
3P30CA046592-28S2
|
$499,325
|
$9,987
|
LAWRENCE, THEODORE
|
UNIVERSITY OF MICHIGAN
|
|
University of Michigan Comprehensive Cancer Center Support Grant
|
4P30CA046592-28
|
$6,209,909
|
$124,198
|
LAWRENCE, THEODORE
|
UNIVERSITY OF MICHIGAN
|
|
University of Hawaii Cancer Center CCSG
|
3P30CA071789-17S1
|
$115,495
|
$6,930
|
RAMOS, JOE
|
UNIVERSITY OF HAWAII AT MANOA
|
|
University of Hawaii Cancer Center CCSG
|
3P30CA071789-17S2
|
$200,000
|
$12,000
|
RAMOS, JOE
|
UNIVERSITY OF HAWAII AT MANOA
|
|
University of Hawaii Cancer Center CCSG
|
4P30CA071789-17
|
$1,913,800
|
$114,828
|
RAMOS, JOE
|
UNIVERSITY OF HAWAII AT MANOA
|
|
University of Colorado NTCN Lead Academic Participating Site (LAPS)
|
5U10CA180834-03
|
$768,950
|
$38,448
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
Understanding the AGL metastasis suppressor for therapeutic gain
|
2R01CA143971-06
|
$427,627
|
$427,627
|
THEODORESCU, DAN
|
UNIVERSITY OF COLORADO DENVER
|
|
Understanding barriers to single-dose intravesical chemotherapy in non-muscle invasive bladder cancer
|
1K23CA212272-01
|
$145,163
|
$145,163
|
CARY, KELLY
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
UM LAPs- U10 Grant
|
5U10CA180801-03
|
$682,727
|
$34,136
|
ZALUPSKI, MARK
|
UNIVERSITY OF MICHIGAN
|
|
UCDCCC NCTN U10 Program
|
5U10CA180846-03
|
$626,991
|
$15,675
|
GANDARA, DAVID
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
Translational Surgical Pathology
|
ZIE SC 000853
|
$211,049
|
$14,773
|
Merino, Maria
|
CCR (NCI)
|
|
Translational Research in Cancer
|
3P30CA056036-17S1
|
$117,000
|
$2,340
|
KNUDSEN, KAREN
|
THOMAS JEFFERSON UNIVERSITY
|
|
Translational Research in Cancer
|
4P30CA056036-17
|
$2,807,751
|
$56,155
|
KNUDSEN, KAREN
|
THOMAS JEFFERSON UNIVERSITY
|
|
Towards a non-invasive molecular test for bladder cancer
|
5R01CA116161-07
|
$373,691
|
$373,691
|
GOODISON, STEVE
|
MAYO CLINIC JACKSONVILLE
|
|
Tobacco Companies, Public Policy and Global Health
|
5R01CA091021-13
|
$489,933
|
$24,497
|
LEE, KELLEY
|
SIMON FRASER UNIVERSITY
|
|
Tissue Processing-Sequencing Facility
|
ZIC BC 011044
|
$444,333
|
$44,433
|
Vocke, Cathy
|
CCR (NCI)
|
|
The Global Diffusion of Tobacco Control
|
4R01CA157577-05
|
$342,115
|
$17,106
|
VALENTE, THOMAS
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Targeting the plasma high density lipoprotein (SR-B1) receptor for effective anti-cancer therapeutics.
|
1R43CA203170-01
|
$220,726
|
$220,726
|
MCCONATHY, WALTER
|
LIPOMEDICS, INC.
|
|
Targeting the MET pathway in urothelial carcinoma
|
ZIA BC 011594
|
$539,065
|
$539,065
|
Apolo, Andrea
|
CCR (NCI)
|
|
Targeting the ICOS/ICOSL pathway to improve anti-tumor immune responses
|
4R01CA163793-05
|
$327,850
|
$163,925
|
SHARMA, PADMANEE
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Targeting Metabolic Pathways in Bladder Cancer
|
ZIA BC 011741
|
$107,617
|
$107,617
|
Agarwal, Piyush
|
CCR (NCI)
|
|
Targeting mechanisms of radiation resistance
|
ZIA BC 011552
|
$372,064
|
$186,032
|
Citrin, Deborah
|
CCR (NCI)
|
|
SWOG Network Group Operations Center of the NCTN
|
3U10CA180888-03S1
|
$308,895
|
$6,178
|
BLANKE, CHARLES
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
SWOG Network Group Operations Center of the NCTN
|
5U10CA180888-03
|
$5,204,873
|
$104,097
|
BLANKE, CHARLES
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Stanford University NCTN- Network Lead Academic Site
|
5U10CA180816-03
|
$490,000
|
$12,250
|
WAKELEE, HEATHER
|
STANFORD UNIVERSITY
|
|
SPORE in Genitourinary Cancer
|
4P50CA091846-15
|
$1,910,080
|
$1,910,080
|
DINNEY, COLIN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-30S1
|
$116,250
|
$1,163
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-30S2
|
$118,976
|
$1,190
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-30S3
|
$92,737
|
$927
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-30S4
|
$16,666
|
$167
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-30S5
|
$200,000
|
$2,000
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
5P30CA023100-30
|
$3,812,307
|
$38,123
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Sh3gl2 and chemosensitivity of bladder cancer
|
1R21CA198722-01A1
|
$282,050
|
$282,050
|
ADAM, ROSALYN
|
CHILDREN'S HOSPITAL CORPORATION
|
|
SEVERABLE FUNDING FOR NCI-FREDERICK
|
261200800001E
|
$248,730,791
|
$169,607
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
SBIR grant application to develop and commercialize a urine based medical diagnostic for the detection of bladder cancer recurrence.
|
1R44CA200174-01A1
|
$291,776
|
$291,776
|
LEVIN, TREVOR
|
UROLOGY DIAGNOSTICS, INC.
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
3P30CA016056-39S1
|
$131,625
|
$2,633
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
3P30CA016056-39S2
|
$118,659
|
$2,373
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
3P30CA016056-39S3
|
$99,902
|
$1,998
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
3P30CA016056-39S4
|
$199,940
|
$3,999
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
Total relevant funding to Bladder for this search: $33,995,868
|